The Office of Drug Control (ODC) has licensed Cann Group to begin commercial cultivation at its new production facility near Mildura.

The ODC permit has been issued under its recently revised single licence regulatory framework, meaning Cann has now been transitioned to a perpetual licence at all three of its production and research facilities.

Cann Group CEO Peter Crock at the company’s Mildura facility

The permit allows for cultivation and production of medicinal cannabis and research activities. A separate permit covering the manufacture of medicinal cannabis products at Mildura is expected to be issued in the near future.

Cann is now preparing to transfer medicinal cannabis plants from its Southern facility to Mildura to establish starting genetics, with the first commercial crop due to be harvested by June 2022. It will feed into the company’s extraction activities at Mildura utilising its GMP-designed manufacture suite and equipment.

While final fit-out and commissioning activity will continue in some areas of the facility, the site has been handed over by the principal builder and an occupancy certificate has been issued.

CEO Peter Crock said: “The completion of works in the cultivation areas and our transition into commercial production activity is a major milestone for Cann. Along with the granting of the ODC permits, it represents a tremendous achievement on the part of our project development and regulatory teams. 

“Our investment in new technology and scale will generate important benefits, including cost efficiencies that will help make Cann globally competitive.

“As we ramp up commercial production, we will expand our market development activities with the aim of quickly growing our customer and revenue base, capitalising on the scale, cost and quality benefits that Mildura provides.” 

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...